Price range: $54.99 through $259.99
Research Studies
Tirzepatide 20 mg is supplied at 99%+ purity for in-vitro laboratory research only. Not for human or veterinary use.
Reconstituting this vial? Our free peptide reconstitution calculator converts vial mass and diluent volume into concentration, draw volume and U-100 syringe graduations. Research use only.
Tirzepatide is a synthetic research peptide studied in metabolic signaling models and receptor interaction pathways across GLP-1 and GIP receptors. Supplied as a lyophilized powder for controlled laboratory research only. 99%+ purity, third-party tested, Certificate of Analysis included with every order. Not for human or animal consumption.
| Weight | 15 lbs |
|---|---|
| Size | 10 mg, 20 mg, 30 mg, 40 mg, 100 mg |
| CAS No. | 2023788-19-2 |
| Purity | ≥99% |
| Sequence | Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser |
| Molecular Formula | C225H348N48O68 |
| Molecular Weight | 4813.45 g/mol |
| Synthesis | Solid-phase synthesis |
| Format | Lyophilized powder |
| Solubility | Soluble in water or 1% acetic acid |
| Stability & Storage | Stable for up to 24 months at -20°C. After reconstitution, may be stored at 4°C for up to 4 weeks or at -20°C for up to 6 months. |
| Applications | Dual GIP/GLP-1 receptor research, incretin signaling studies, glucose and energy homeostasis models |
| Appearance | White lyophilized powder |
| Shipping Conditions | Shipped at ambient temperature; once received, store at -20°C |
| Regulatory/Compliance | Produced in compliance with cGMP guidelines |
| Safety Information | Refer to provided MSDS |
Use bacteriostatic water (BAC) at a 1–2 mL volume per vial. Add the solvent slowly down the vial wall, swirl gently — never shake. Refrigerate after reconstitution and use within 30 days. For in-vitro laboratory handling only.
Lyophilized: 36–46°F (refrigerated) for up to 24 months. Reconstituted: keep refrigerated and protect from light; use within 30 days. Avoid repeated freeze-thaw cycles.
Orders placed before 3 PM EST ship the same business day from our USA facility. Tracking is emailed within 24 hours. Plain, discreet packaging. Free shipping on orders over $150.
For Research Use Only · Not for human consumption
For laboratory teams evaluating where to buy tirzepatide for research, the priority is documentation, compound identity, and research-use-only (RUO) alignment — not consumer positioning. Tirzepatide (development code LY-3298176) is a synthetic 39‑amino‑acid peptide catalogued by PubChem with the molecular formula C225H348N48O68 and a molecular weight of approximately 4,813 g/mol (PubChem CID 166567236)[1]. It carries a C20 fatty di-acid moiety and is described in the literature as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist[2][3]. This product-page guide explains how tirzepatide is framed for controlled research procurement while keeping documentation review separate from non-laboratory intent.
Researchers evaluating where to buy tirzepatide for research should review RUO labeling, a batch-specific certificate of analysis (COA), HPLC purity data, LC-MS or comparable identity support, sequence/formula consistency, and lot traceability before procurement. Material discussed here is intended for laboratory research use only and is not for human or veterinary use. The safest evaluation lens is documentation-first, not outcome-first.
In this context the phrase is addressed as laboratory research-procurement intent. It refers to how qualified researchers, institutions, and technical buyers evaluate a tirzepatide reference material through documentation, analytical support, and labeling clarity — not personal, clinical, or consumer decision-making. The first review layer is compound identity, COA availability, lot-number alignment, and test-method transparency.
Tirzepatide should be evaluated at the product and batch level. The identity record on the product page, label, and COA should tell one consistent story across name, sequence notation, molecular formula, and mass.
| Compound name | Tirzepatide (LY-3298176) |
| PubChem CID | 166567236[1] |
| CAS number | 2023788-19-2 |
| Molecular formula | C225H348N48O68[1] |
| Molecular weight | ≈ 4,813 g/mol[1] |
| Residues / format | 39-amino-acid synthetic peptide; C20 fatty di-acid moiety |
| Receptor class (literature) | Dual GIP / GLP-1 receptor agonist[2][3] |
| Product form | Lyophilized powder |
| Purity target | ≥ 99% (see batch-specific COA) |
| Regulatory status | Research use only — not for human or veterinary use |
Peer-reviewed literature describes tirzepatide within incretin-receptor pharmacology. The discovery and characterization work reported it as a dual GIP and GLP-1 receptor agonist[2], and later receptor-pharmacology analysis described it as an imbalanced, biased agonist with relatively greater activity at the GIP receptor than the GLP-1 receptor[3]. On a research product page this pathway context should remain academic literature interpretation used to define the receptor lane — it is not converted into product-performance language.
A tirzepatide COA should be reviewed as a batch-specific record, not a general marketing statement. Look for compound name, lot number, test date, stated purity, analytical method, identity confirmation, and molecular information. Purity percentage alone does not establish identity; purity, identity, method, and lot number should be evaluated together.
| Evaluation area | What to review | Why it matters for RUO procurement |
|---|---|---|
| RUO labeling | Clear research-use-only language on page and label | Separates research procurement from human-use positioning |
| COA availability | Batch-specific certificate for the received lot | Supports lot-level documentation and quality review |
| Purity data | HPLC area-percent support for the stated purity | Helps evaluate material consistency |
| Identity testing | LC-MS / mass-spec confirmation vs expected mass | Confirms the material matches the listed peptide |
| Lot traceability | Lot number matching across records | Supports research recordkeeping |
HPLC documentation supports purity assessment and chromatographic separation review; LC-MS or mass-spectrometry documentation supports identity confirmation and molecular-mass review[10][11]. For a 39-residue peptide with a fatty-acid modification, complementary methods are especially useful: HPLC characterizes the purity profile while mass data confirm the observed mass against the expected value. Analytical-procedure frameworks such as ICH Q2(R2) describe validation characteristics used to interpret assay, purity, and identity results[7].
Lot traceability connects the product listing, COA, label, and receiving record. When the same lot number appears consistently across records, the laboratory file is easier to verify and maintain. ISO/IEC 17025 addresses the competence and consistent operation of testing laboratories, and NIST resources describe how certificates and lot identifiers support traceability in reference-material contexts[8][9].
| Research-safe statement | Non-compliant version to avoid |
|---|---|
| “Tirzepatide is discussed in published literature on GIP/GLP-1 receptor pharmacology.” | “Tirzepatide helps with weight or blood sugar.” |
| “Researchers should review COA and identity data before procurement.” | “Buy tirzepatide for results.” |
| “Greatest Peptides supplies tirzepatide as a research-use-only material.” | “Greatest Peptides supplies tirzepatide for treatment.” |
Greatest Peptides supplies tirzepatide as a research-use-only laboratory material in lyophilized powder form, positioned around a stated ≥99% purity target, batch-specific COA availability, HPLC/LC-MS documentation, lot-level traceability, and transparent RUO labeling. Products are not intended for human or animal consumption, diagnostic, therapeutic, clinical, or veterinary use. Researchers are responsible for lawful, appropriate handling under applicable regulations and institutional guidelines.
Published tirzepatide literature spans discovery chemistry, receptor pharmacology, and clinical study programs[2][3][4][5]. This literature is useful for understanding how the compound is characterized in scientific settings. Published clinical literature is outside the scope of RUO product positioning and should not be interpreted as use guidance for research-use-only materials. Regulated medicines, clinical-study materials, and RUO materials are not interchangeable.
Compound profile
Tirzepatide in one paragraph
Tirzepatide is a synthetic 39-residue peptide that acts as an agonist at both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Structurally it is built on the GIP backbone rather than the GLP-1 backbone, which is the single fact that explains most of its pharmacology and most of the confusion about it. It is the best-characterized dual incretin agonist in the published record, which makes it the natural reference compound when a multi-receptor effect needs to be separated from a single-receptor one. Everything below describes the research literature. It is not guidance, and it is not applicable to any use in humans or animals.
The design history of tirzepatide begins with a negative result. Through the 1990s and 2000s the GIP receptor was widely regarded as a poor drug target in metabolic disease, partly because GIP secretion is preserved or elevated in type 2 diabetes while its insulinotropic effect is blunted, and partly because GIP-receptor knockout animals were resistant to diet-induced obesity, which pointed the wrong way. The prevailing conclusion was that GIP-receptor agonism would be unhelpful and possibly counterproductive.
What changed the picture was a series of reports that GIP-receptor and GLP-1-receptor agonism given together produced effects that neither produced alone, and that the blunted GIP response in diabetes could be restored once glycemia improved. That reframed GIP-receptor agonism as something that might work in combination even though it did not work in isolation. The molecule that came out of that reframing, from Eli Lilly, was described in the literature as LY3298176 before it received the name tirzepatide.
The engineering decision that distinguishes it is the choice of backbone. Rather than modifying GLP-1 to pick up GIP-receptor affinity, the program modified GIP to pick up GLP-1-receptor affinity. GIP and GLP-1 share meaningful sequence homology in the region that engages the receptor extracellular domain, so this was feasible, and it produced a molecule with an unbalanced rather than a balanced activity profile: closer to native GIP in potency at the GIP receptor, and weaker than native GLP-1 at the GLP-1 receptor.
The specification table on this page carries the sequence, molecular formula and molecular weight recorded for this listing. What that string encodes, read structurally, is four deliberate departures from the native GIP sequence.
Two positions near the N-terminus carry alpha-aminoisobutyric acid in place of the native residues. The substitution at the second position is the one that blocks dipeptidyl peptidase-4, which would otherwise remove the first two residues and destroy activity within minutes. The second such substitution, further along, stabilizes the helical conformation the peptide adopts when bound.
A lysine side chain in the mid-sequence region carries a C20 fatty diacid, attached not directly but through a linker built from glutamic acid and two units of a short polyethylene-glycol-like spacer. The diacid binds albumin; the spacer holds it far enough from the backbone that it does not interfere with receptor engagement. This is the module that converts a peptide with a half-life of minutes into one with a half-life measured in days, and it is also what makes the molecule surface-active on the bench.
The C-terminus is amidated rather than carrying a free carboxylate. And a small number of mid-sequence substitutions relative to native GIP are what create the GLP-1-receptor affinity, since native GIP has essentially none.
One further property is reported for this molecule that is not visible in the sequence at all. At the GLP-1 receptor, tirzepatide has been described as a biased agonist, producing cyclic AMP accumulation while recruiting beta-arrestin less efficiently than a balanced agonist would, which reduces receptor internalization. Whether that bias is functionally important is one of the live questions in the field.
The GIP receptor and the GLP-1 receptor are both class B G-protein-coupled receptors that couple to Gs and raise cyclic AMP, and both are expressed on pancreatic beta cells, which is where their shared insulinotropic effect originates. Beyond that overlap their distributions diverge in ways that matter.
The GLP-1 receptor is densely expressed in the hindbrain, in the area postrema and the nucleus tractus solitarius, and in the hypothalamic arcuate nucleus, and this central expression is where most of the food-intake literature localizes its effect. It is also present in the gastrointestinal tract, where its activation slows gastric emptying, and in the heart and kidney.
The GIP receptor is expressed on beta cells, on adipocytes, and centrally in the hypothalamus, and its role in adipose tissue is the most genuinely unresolved question in this area of the literature. Agonism and antagonism at the GIP receptor have both been reported to reduce body weight in animal models, which is not a contradiction anyone has cleanly resolved. Candidate explanations include receptor desensitization under sustained agonism producing a functional antagonism, tissue-specific differences between central and peripheral GIP receptors, and genuine differences between acute and chronic signaling. Any paper you read on tirzepatide's adipose effects sits somewhere in that dispute, and it is worth identifying where.
Because the molecule's activity is unbalanced, favoring the GIP receptor, its composite pharmacology is not what you would predict from a balanced co-agonist. This is the reason the correct comparators in a tirzepatide experiment are a GLP-1-selective agonist and, where available, a GIP-selective agonist, run in the same system.
Tirzepatide has the deepest literature of any multi-receptor incretin agonist, and it is unusually well stratified.
The foundational pharmacology papers characterize cyclic AMP accumulation and beta-arrestin recruitment at both human receptors in recombinant cell systems, establish the imbalance in favor of the GIP receptor, and report the signaling-bias observation at the GLP-1 receptor. These are the papers to cite for potency and selectivity, and they are also where the assay-condition caveats are stated most carefully.
A second body of work uses the compound in rodent models with a comparator set, addressing food intake, energy expenditure by indirect calorimetry, insulin secretion in isolated islets, adipose tissue gene expression and lipid handling, and receptor-knockout designs that attempt to assign each observed effect to one receptor or the other. The knockout studies are the most informative single category for mechanism and the least often cited in secondary discussion.
A third body is clinical, spanning the diabetes and obesity trial programs reported from 2018 onward. These are human-outcome papers. They establish nothing about the molecule as a reagent and should not be used as bench references, however frequently they are quoted on retail pages.
A fourth and growing body uses tirzepatide as the reference dual agonist against which newer multi-agonists are measured. If you are reading a paper about a triple agonist, tirzepatide is very likely the comparator, and the comparison is only interpretable if both were run in the same assay.
Four specific misreadings account for most of the wrong statements made about this compound.
The first is describing it as a GLP-1 agonist, or worse as a semaglutide variant. It is built on GIP, it is more potent at the GIP receptor than at the GLP-1 receptor, and its pharmacology is not a stronger version of a GLP-1 agonist's. The description matters in a methods section because a reader who takes it as a GLP-1 tool compound will misinterpret the controls.
The second is treating the GIP-receptor question as settled. It is not. The coexistence of reports that both GIP-receptor agonism and GIP-receptor antagonism reduce adiposity in animal models is an open problem, and secondary sources routinely present one side of it as established fact.
The third is over-reading the signaling-bias observation. Reduced beta-arrestin recruitment relative to a comparator is a measurement made in a specific recombinant system with a specific readout. Whether it explains anything about the compound's behavior in tissue is an active question, not a conclusion, and bias metrics are notoriously sensitive to the choice of reference ligand and to receptor expression level.
The fourth is comparing potency figures across papers. The same caution applies here as to every class B receptor agonist: half-maximal effective concentrations for these molecules shift by an order of magnitude with expression level, incubation time and whether phosphodiesterase inhibition is present. Numbers from different laboratories are not comparable, and constructing a potency ranking from a literature survey is not a valid procedure.
Tirzepatide's bench behavior is governed by its fatty diacid, which makes it amphiphilic and therefore surface-active. Three consequences dominate.
Surface adsorption is substantial. A dilute solution stored or handled in ordinary plastic loses peptide to the container wall, and the fractional loss rises as concentration falls because the amount adsorbed depends on surface area rather than on how much is in solution. Low-binding labware, minimal transfer steps and preparing working dilutions immediately before use all reduce this. Where a carrier protein is acceptable in the assay matrix it reduces it further, at the cost of changing the matrix.
Self-association means nominal concentration and monomer concentration are different quantities. Acylated incretin analogs form oligomeric species whose distribution depends on pH, ionic strength, temperature and the presence of phenolic compounds. Whether that matters depends entirely on what your assay reads.
Interface stress during freezing and thawing is the most common avoidable cause of loss, and repeated freeze-thaw of a stock is worse than any other single handling decision. Aliquot once into the volumes you will actually consume.
Solubility of the free peptide is pH-dependent and is poorest near its isoelectric point. The solubility and storage statements printed in the specification table above come from the product record for this listing; verify them against the documentation supplied with the lot rather than treating a catalog row as an independent measurement.
The analytical profile of tirzepatide is dominated by the fatty-acid chain. On a reversed-phase column the molecule is strongly retained and elutes late, requiring a high organic proportion, and its peak is intrinsically broader than a short unmodified peptide's because oligomeric species interconvert during the separation. Interpreting that breadth as impurity is a routine error.
The impurities that are analytically hardest, and therefore the ones documentation should speak to, are those that are structurally close to the target: deamidation products, oxidation products, sequence variants from incomplete coupling, and species in which the fatty diacid is absent, truncated, or conjugated at the wrong lysine. The unconjugated peptide is much less retained and is usually resolvable; a wrongly positioned conjugate may not be, and it has the same mass as the correct molecule, which means mass spectrometry alone does not exclude it.
That last point is worth being explicit about, because it is the main reason a purity number and an identity confirmation are not interchangeable. A mass spectrum tells you the molecule has the expected composition. A chromatogram tells you how much of the sample runs as a single species. Neither tells you the isomer is correct, and a certificate that reports only the two of them is silent about a class of defect specific to acylated peptides.
For quantitation, note that content and purity are different measurements. Purity is a relative area figure; content is the fraction of the weighed mass that is peptide rather than trifluoroacetate or acetate counter-ion, residual water and salt. For an acylated peptide the gap between the two can be substantial, and it is content, not purity, that determines what a given weighed mass actually delivers.
| Often mistaken for | How it actually differs from Tirzepatide |
|---|---|
| Semaglutide | Built on the GLP-1 backbone and selective for the GLP-1 receptor. It is the correct control for isolating the GLP-1 component of a tirzepatide effect, and it is a different molecule with a different receptor profile, not a weaker version of the same thing. |
| Retatrutide | Adds glucagon-receptor agonism to the same structural design language. Useful as the next comparator up when asking whether an effect requires a third receptor, but with a much thinner independent literature. |
| Native GIP | The endogenous 42-residue hormone. It is cleaved by dipeptidyl peptidase-4 within minutes, carries no fatty acid, and has essentially no GLP-1 receptor affinity. Data generated with native GIP does not transfer. |
| GIP receptor antagonists | A separate and actively pursued approach that also reduces adiposity in animal models. Their existence is the clearest sign that the GIP arm of this pharmacology is not a settled question, and they are sometimes cited as though they supported the agonist rationale. |
No, and this is the most consequential misdescription in circulation. It is a GIP analog that has been modified to also engage the GLP-1 receptor. Its potency at the GIP receptor is closer to native GIP than its potency at the GLP-1 receptor is to native GLP-1, so the imbalance runs toward GIP. Describing it as a GLP-1 analog will lead a reader to expect the wrong comparators.
In recombinant assays tirzepatide has been reported to drive cyclic AMP accumulation at the GLP-1 receptor while recruiting beta-arrestin less efficiently than a balanced agonist, which is associated with less receptor internalization. That is a measurement in a defined system, not an established mechanism of action, and bias calculations depend heavily on the reference ligand and receptor expression level.
Because it genuinely is unresolved. Both agonism and antagonism at the GIP receptor have been reported to reduce adiposity in animal models. Proposed reconciliations include desensitization under sustained agonism amounting to functional antagonism, differences between central and peripheral receptor populations, and differences between acute and chronic signaling. No single explanation has consensus.
Not reliably. Class B receptor potency figures move by an order of magnitude with assay conditions, and cross-paper comparison is a well-known source of error for these molecules. If the comparison is load-bearing for your conclusion, the compounds need to be run side by side in one assay.
Identity by mass spectrometry and purity by reversed-phase HPLC are the baseline, but for an acylated peptide neither addresses conjugation position, since a misplaced fatty acid has the correct mass and may co-elute. Documentation that speaks to the conjugation specifically, or a method resolved enough to separate positional isomers, tells you more here than it would for an unmodified peptide. Content, as distinct from purity, is the other figure most often missing.
The section above covers what Tirzepatide is and what the published literature has looked at. This section is the operational half: what physically arrives when you order this listing, what paperwork comes with it, which fields on that paperwork are worth reading closely, and how to log the material once it is on your bench. It is written for the person who has already decided the compound is relevant and now has to justify the purchase to a supervisor, a grant line or an internal quality process.
Everything below is scoped to this exact listing rather than to research peptides in general. If you want the general version — how to read a certificate of analysis from scratch, what HPLC and mass spectrometry each prove, how to compare two suppliers who both claim 99% — that is on the home page guide, and there is no reason to read it twice.
One sealed vial of lyophilized material at the listed 20 mg fill, labeled for research use only, dispatched within 24 hours of the order clearing. Batch documentation is available for the lot you receive. Free shipping applies at $150 and above.
This listing is a single fixed presentation, not a size selector. That is deliberate: each presentation gets its own page, its own documentation trail and its own URL, so a citation or a purchase-order line that points at Tirzepatide at 20 mg points at exactly one thing. If you need a different fill of the same compound and it is not listed, it is not currently in stock rather than hidden behind a dropdown.
| Field | This listing |
|---|---|
| Listing | Tirzepatide |
| Labeled fill mass | 20 mg |
| Physical form | Lyophilized powder in a sealed vial |
| Catalog category | GLP-1 / Incretin Class Analogs |
| Compound class | Incretin-class analog |
| Intended use | Research use only. Not for human or veterinary use, not for diagnostic use, not a drug or supplement. |
| Dispatch | Within 24 hours of the order clearing |
| Documentation | Batch analytical documentation available for the lot supplied |
| Free shipping threshold | Orders of $150 and above |
The table below is the specification the store publishes for this listing. It is reproduced here from the product record itself rather than retyped, which means it cannot drift away from what the attribute table further up the page says. Where a field is absent it is absent because we do not publish it for this SKU, not because it was left out of this summary.
| Size | 10 mg, 20 mg, 30 mg, 40 mg, 100 mg |
| CAS No. | 2023788-19-2 |
| Purity | ≥99% |
| Sequence | Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser |
| Molecular Formula | C225H348N48O68 |
| Molecular Weight | 4813.45 g/mol |
| Synthesis | Solid-phase synthesis |
| Format | Lyophilized powder |
| Solubility | Soluble in water or 1% acetic acid |
| Stability & Storage | Stable for up to 24 months at -20°C. After reconstitution, may be stored at 4°C for up to 4 weeks or at -20°C for up to 6 months. |
| Applications | Dual GIP/GLP-1 receptor research, incretin signaling studies, glucose and energy homeostasis models |
| Appearance | White lyophilized powder |
| Shipping Conditions | Shipped at ambient temperature; once received, store at -20°C |
| Regulatory/Compliance | Produced in compliance with cGMP guidelines |
| Safety Information | Refer to provided MSDS |
A specification table is a claim, and a claim is only worth the record behind it. Every field above is one you can ask us to substantiate against the batch documentation for the lot you were sent. If a field ever fails to match the paperwork, that is a defect on our side and we would rather hear about it than not.
Incretin-class analogs are long-chain sequences with modifications that are easy to get almost right and hard to get exactly right. A mass that lands a few hundred daltons away from the expected value usually means a truncated or incorrectly modified chain rather than a weighing error, which is why the mass-spectrometry trace matters more here than on a short peptide.
A certificate of analysis is not a quality badge. It is a measurement report about one specific batch, produced on a specific date by a specific method, and its value to you is entirely a function of how much of that context it discloses. For Tirzepatide the fields worth checking first are the ones that tie the document to the container in your hand.
| Field on the certificate | Why it matters for this SKU |
|---|---|
| Lot or batch identifier | Ties the document to the vial. A certificate with no lot reference describes some batch, not necessarily yours. |
| Compound name and, where applicable, sequence | This is the identity claim. For a incretin-class analog it is the field that distinguishes the material from its close relatives. |
| Analytical method and conditions | A purity figure without a method is a number without units. Column, gradient and detection wavelength change what the figure means. |
| Date of analysis | Establishes how old the measurement is relative to the material. A recent vial with a two-year-old certificate is a documentation gap. |
| Who performed the analysis | In-house and independent third-party results are both legitimate; they are not the same claim, and the document should say which it is. |
| The chromatogram or spectrum itself | A summary table can be typed by anyone. A trace can be read, and a reader who knows the compound class can tell whether it is plausible. |
What our documentation for Tirzepatide does assert is what the analysis measured on the batch that was tested. What it does not assert — and no certificate from any supplier can assert — is that the material is safe, that it is suitable for any use in humans or animals, or that it will reproduce a result reported in a published paper. Those are different questions and a purity figure is not evidence for any of them.
Our batch documentation policy, including how to request the record for a lot you already have, is on the certificate of analysis page. If you need the record before ordering rather than after, ask us through the contact page and reference this listing by name.
Three questions have to be answered separately before a compound gets a page here, and collapsing them into one percentage is the most common way a supplier listing becomes misleading.
| Question | What answers it | What it does not tell you |
|---|---|---|
| Identity — is this the right molecule? | Mass determination, and sequence confirmation where the material is a defined chain | Nothing about how much of the vial is that molecule |
| Purity — what proportion of the detected material is the target? | Chromatographic separation with a stated method | Nothing about what the other fraction actually is, unless the impurities are themselves identified |
| Content — how much target material is actually in the container? | Quantitative determination against the labeled fill | Nothing about identity or purity; a vial can be accurately filled with the wrong thing |
For Tirzepatide, receptor activation assays, cell-based cAMP or beta-arrestin readouts, and metabolic endpoint work in animal models are the assay formats the published work in this area tends to use, which matters when you are deciding whether the material as supplied is fit for the experiment you have in mind. A compound that is clean enough for a binding assay is not automatically clean enough for a quantitative cell-based readout where a co-eluting impurity could carry activity of its own.
Content is the field most often missing from a supplier listing, and it is the one that changes your arithmetic. A vial labeled 20 mg contains that much total solid, and total solid includes counter-ion, residual water and whatever else survived the process. If you need the peptide mass rather than the vial mass to be exact, that is a specific request to make in advance, not an assumption to carry into a calculation.
The most useful five minutes you will spend on this material are the five minutes immediately after the package is opened, because that is the only moment at which you can still distinguish a transit problem from a handling problem of your own.
Longer modified chains in this class are typically the least tolerant of repeated warming in the catalog, so aliquot planning before the first reconstitution is worth more here than almost anywhere else.
The general rule for lyophilized material is that the dry state is the stable state and every transition away from it costs you something. Freeze-thaw cycling is the specific mechanism most likely to degrade Tirzepatide after it reaches you, and it is entirely under your control: a single reconstitution split into pre-planned aliquots exposes the material once, while repeatedly warming and refreezing one container exposes it as many times as you open it. There is a fuller treatment of the mechanism in our guide on freeze-thaw cycles in peptide research materials and on storage and handling.
This is arithmetic, not guidance. The only thing the table below does is tell you what concentration you are holding after you have added a known volume of diluent to a vial labeled 20 mg, so that the figure in your notebook and the figure in the container are the same figure. It says nothing about how much material any experiment should use, and it is not applicable to any use in humans or animals.
| Diluent added | Resulting concentration | Amount in 0.1 mL | Amount in 0.05 mL | Aliquots of 0.25 mL |
|---|---|---|---|---|
| 1 mL | 20 mg/mL | 2,000 µg | 1,000 µg | 4 |
| 2 mL | 10 mg/mL | 1,000 µg | 500 µg | 8 |
| 3 mL | 6.67 mg/mL | 666.7 µg | 333.3 µg | 12 |
| 5 mL | 4 mg/mL | 400 µg | 200 µg | 20 |
Every figure above is the same division: the labeled mass of Tirzepatide divided by the volume of diluent added. Nothing in the table is a recommendation about how much material to use in an experiment — it is the arithmetic that tells you what concentration you are holding once you have added a known volume, so that the number you write in the notebook matches what is in the container.
Two things routinely go wrong at this step. The first is treating the labeled mass as the peptide mass; as noted above, the labeled figure is total solid unless the documentation says otherwise, so a concentration derived from it is a nominal concentration. Say so in your methods rather than implying a precision the specification does not support. The second is ignoring the volume the solid itself occupies — small at these masses, but not zero, and it means the final volume is very slightly greater than the volume you added.
If you want to work backwards from a target concentration to a diluent volume, or to check a figure against a different vial size, our peptide reconstitution calculator does the same division in both directions and shows its working.
Reproducibility in this area fails at the material-provenance step far more often than at the analysis step. The fields below are the ones that let somebody else — a reviewer, a collaborator, or you in eighteen months — work out whether two sets of results were generated with comparable material.
Comparing Tirzepatide across suppliers on price alone is comparing two numbers that may not describe the same thing. These are the questions that make the comparison meaningful, with our answers next to them so you can hold us to the same standard you would hold anyone else.
| Question to ask any supplier | Our answer for this listing |
|---|---|
| Is batch documentation available for the specific lot I will receive, not a representative lot? | Yes — the record is tied to the lot supplied. Policy on the certificate of analysis page. |
| Does the analytical method appear on the document, or only the result? | The method context belongs on the document; a bare percentage is not a complete record. |
| Is the labeled figure total solid or target-compound mass? | Labeled as the fill for this presentation. If you need the distinction resolved for a calculation, ask before ordering. |
| Is the listing labeled research use only throughout, without use claims? | Yes, and deliberately so. No use, benefit or outcome is claimed anywhere on this page. |
| How quickly does it dispatch, and is that a promise or an average? | Within 24 hours of the order clearing. |
| Can I reach a person about the paperwork rather than only about the order? | Yes — the contact page reaches us directly. |
| Is there a published position on what the documentation does not prove? | Yes. It is stated on this page and on every product page. |
A supplier who answers all seven honestly is a better bet than a supplier who is ten percent cheaper and answers four. A supplier who cannot answer the first one at all is not selling you documented material; they are selling you a container.
Tirzepatide is supplied for laboratory research use only. It is not a drug, not a supplement, not a cosmetic and not a medical device. It is not for human or veterinary administration, not for diagnostic use, and not for use in food. That is not a disclaimer bolted onto a sales page — it is the actual scope of what is being sold, and it constrains what can honestly be written about it.
| Language that stays inside the boundary | Language that does not |
|---|---|
| "Supplied for research use only" | Any phrasing that implies a personal or clinical use |
| "Published work in this area has examined receptor binding, signaling selectivity and metabolic endpoints in incretin-pathway models" | "Tirzepatide does X" stated as an established effect |
| "Purity determined by the stated method on the tested batch" | "Pharmaceutical grade", "medical grade", "safe" |
| "Concentration arithmetic for preparing laboratory aliquots" | Anything framed as a dose, a protocol or a schedule |
| "Not for human or veterinary use" | Silence on the point, which readers correctly interpret as evasion |
| Naming the model system a finding came from | Reporting an animal or in-vitro finding as though it were a human finding |
The reason to be precise about this is not only regulatory. Research literature on this class of material is genuinely interesting and genuinely incomplete, and overstating it makes the real findings harder to see. Where published work is referenced on this site it is referenced as what was measured, in what system, at what scale — not as a property of the vial.
These share a catalog category with Tirzepatide, which means the documentation and handling considerations above largely transfer to them. Their compound-specific sections do not — each has its own identity, its own literature and its own analytical profile.
| Listing | Price |
|---|---|
| Retatrutide | Price range: $79.99 through $219.99 |
| Semaglutide | Price range: $39.99 through $89.99 |
The full catalog is on the shop page, and the longer written material is in our research guides.
Yes. Ask through the contact page and reference this listing by name. Our general position on batch documentation is on the certificate of analysis page. If a supplier will not show you the record until after payment has cleared, that is worth noticing.
It is the labeled fill for this presentation. For lyophilized material the labeled mass is total solid unless the documentation states otherwise, and total solid includes counter-ion and residual moisture as well as target compound. If your calculation depends on the distinction, resolve it against the batch record rather than assuming.
Within 24 hours of the order clearing. Orders of $150 and above ship free. Transit time after dispatch depends on the service selected at checkout.
No. This material is supplied for laboratory research use only. It is not a drug, supplement or cosmetic, it is not for human or veterinary administration, and nothing on this page should be read as guidance for any such use.
Store the sealed vial dry, dark and at the temperature stated for this listing, and record the date it entered storage. Once material is in solution the useful discipline is to minimize repeated warming: plan the aliquot scheme before the first reconstitution so the material is exposed once rather than once per experiment. Longer modified chains in this class are typically the least tolerant of repeated warming in the catalog, so aliquot planning before the first reconstitution is worth more here than almost anywhere else.
That depends entirely on the concentration your protocol calls for, which is your decision and not something a product page can answer. What the table above provides is the arithmetic: labeled mass divided by added volume gives concentration. The reconstitution calculator runs the same division in either direction.
No, and this is the single most common misreading of a certificate of analysis. Purity describes what proportion of the detected material was the target compound in the batch that was tested, by the method stated. It is not a safety assessment, it says nothing about suitability for any use in humans or animals, and it does not become a safety claim by being a large number.
It is listed as a long modified chain with an acylated or otherwise conjugated residue, in the GLP-1 / Incretin Class Analogs category. Published work in this area has looked at receptor binding, signaling selectivity and metabolic endpoints in incretin-pathway models. That is a description of where the literature sits, not a claim about what the material does.
Yes. The home page guide covers reading a certificate of analysis, what chromatographic and mass-spectrometric methods each prove, and how to compare suppliers. The research guides go deeper on individual topics, and the FAQ covers ordering, shipping and post-shipping questions.
Tirzepatide is supplied strictly for laboratory research use. It is not a drug, supplement, cosmetic or medical device; it is not for human or veterinary use, not for diagnostic use and not for use in food. No statement on this page is intended to describe a therapeutic use, benefit or outcome, and references to published work describe what was measured in the reported model system rather than a property of the material supplied. Purchasers are responsible for handling the material in accordance with the requirements applicable to their institution and jurisdiction.
Our batch documentation policy is published in full, and the reconstitution arithmetic for this vial is one click away. Certificate of analysis policy · Reconstitution calculator · Full catalog